Cargando…
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
SIMPLE SUMMARY: Low cost, reliable predictors of benefit from PARP inhibitors (PARPi) are missing for relapsed BRCA wild-type (WT) ovarian cancer (OC). MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954459/ https://www.ncbi.nlm.nih.gov/pubmed/36831376 http://dx.doi.org/10.3390/cancers15041032 |
_version_ | 1784894122594664448 |
---|---|
author | Tuninetti, Valentina Ghisoni, Eleonora Pignata, Sandro Picardo, Elisa Raspagliesi, Francesco Andreetta, Claudia Maldi, Elena Artioli, Grazia Mammoliti, Serafina Zanchi, Lucia Sikokis, Angelica Biglia, Nicoletta Parisi, Alessandro Mandato, Vincenzo Dario Carella, Claudia Cormio, Gennaro Marinaccio, Marco Puppo, Andrea Paolini, Biagio Borsotti, Lucia Scotto, Giulia Turinetto, Margherita Sangiolo, Dario Di Maio, Massimo Valabrega, Giorgio |
author_facet | Tuninetti, Valentina Ghisoni, Eleonora Pignata, Sandro Picardo, Elisa Raspagliesi, Francesco Andreetta, Claudia Maldi, Elena Artioli, Grazia Mammoliti, Serafina Zanchi, Lucia Sikokis, Angelica Biglia, Nicoletta Parisi, Alessandro Mandato, Vincenzo Dario Carella, Claudia Cormio, Gennaro Marinaccio, Marco Puppo, Andrea Paolini, Biagio Borsotti, Lucia Scotto, Giulia Turinetto, Margherita Sangiolo, Dario Di Maio, Massimo Valabrega, Giorgio |
author_sort | Tuninetti, Valentina |
collection | PubMed |
description | SIMPLE SUMMARY: Low cost, reliable predictors of benefit from PARP inhibitors (PARPi) are missing for relapsed BRCA wild-type (WT) ovarian cancer (OC). MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from 150 patients with high grade serous or endometroid BRCA WT OC treated with niraparib or rucaparib maintenance in 15 centers within MITO group. Ki67 expression was assessed by certified pathologists on tumor tissue at diagnosis and median Ki67 was used as cut-off. 136 patients were included. Median Ki67 was 45.7% (range 1.0–99.9). No statistically significant differences in response to PARPi neither in progression free survival and overall survival were identified between low and high Ki67 subgroups. High Ki-67 at diagnosis cannot discriminate responders to PARPi among OC BRCA WT patients. ABSTRACT: Background: There is compelling need for novel biomarkers to predict response to PARP inhibitors (PARPi) in BRCA wild-type (WT) ovarian cancer (OC). Methods: MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from high grade serous or endometroid BRCAWT OC treated with niraparib or rucaparib maintenance between 2010–2021 in 15 centers. Ki67 expression was assessed locally by certified pathologists on formalin-fixed paraffin embedded (FFPE) tissues. Median Ki67 was used as a cut-off. Results: A total of 136 patients were eligible and included in the analysis. Median Ki67 was 45.7% (range 1.0–99.9). The best response to platinum according to median Ki67 was 26.5% vs. 39.7% complete response (CR), 69.1% vs. 58.8% partial response (PR), 4.4% vs. 1.5% stable disease (SD). The best response to PARPi according to median Ki67 was 19.1% vs. 36.8% CR, 26.5% vs. 26.5% PR, 26.5 vs. 25% SD, 27.9% vs. 16.2% progressive disease (PD). No statistically significant differences in progression free survival (PFS) and overall survival (OS) were identified between low and high Ki67. PFS and OS are in line with registration trials. Conclusions: Ki67 at diagnosis did not discriminate responders to PARPi. |
format | Online Article Text |
id | pubmed-9954459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99544592023-02-25 Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study Tuninetti, Valentina Ghisoni, Eleonora Pignata, Sandro Picardo, Elisa Raspagliesi, Francesco Andreetta, Claudia Maldi, Elena Artioli, Grazia Mammoliti, Serafina Zanchi, Lucia Sikokis, Angelica Biglia, Nicoletta Parisi, Alessandro Mandato, Vincenzo Dario Carella, Claudia Cormio, Gennaro Marinaccio, Marco Puppo, Andrea Paolini, Biagio Borsotti, Lucia Scotto, Giulia Turinetto, Margherita Sangiolo, Dario Di Maio, Massimo Valabrega, Giorgio Cancers (Basel) Article SIMPLE SUMMARY: Low cost, reliable predictors of benefit from PARP inhibitors (PARPi) are missing for relapsed BRCA wild-type (WT) ovarian cancer (OC). MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from 150 patients with high grade serous or endometroid BRCA WT OC treated with niraparib or rucaparib maintenance in 15 centers within MITO group. Ki67 expression was assessed by certified pathologists on tumor tissue at diagnosis and median Ki67 was used as cut-off. 136 patients were included. Median Ki67 was 45.7% (range 1.0–99.9). No statistically significant differences in response to PARPi neither in progression free survival and overall survival were identified between low and high Ki67 subgroups. High Ki-67 at diagnosis cannot discriminate responders to PARPi among OC BRCA WT patients. ABSTRACT: Background: There is compelling need for novel biomarkers to predict response to PARP inhibitors (PARPi) in BRCA wild-type (WT) ovarian cancer (OC). Methods: MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from high grade serous or endometroid BRCAWT OC treated with niraparib or rucaparib maintenance between 2010–2021 in 15 centers. Ki67 expression was assessed locally by certified pathologists on formalin-fixed paraffin embedded (FFPE) tissues. Median Ki67 was used as a cut-off. Results: A total of 136 patients were eligible and included in the analysis. Median Ki67 was 45.7% (range 1.0–99.9). The best response to platinum according to median Ki67 was 26.5% vs. 39.7% complete response (CR), 69.1% vs. 58.8% partial response (PR), 4.4% vs. 1.5% stable disease (SD). The best response to PARPi according to median Ki67 was 19.1% vs. 36.8% CR, 26.5% vs. 26.5% PR, 26.5 vs. 25% SD, 27.9% vs. 16.2% progressive disease (PD). No statistically significant differences in progression free survival (PFS) and overall survival (OS) were identified between low and high Ki67. PFS and OS are in line with registration trials. Conclusions: Ki67 at diagnosis did not discriminate responders to PARPi. MDPI 2023-02-06 /pmc/articles/PMC9954459/ /pubmed/36831376 http://dx.doi.org/10.3390/cancers15041032 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tuninetti, Valentina Ghisoni, Eleonora Pignata, Sandro Picardo, Elisa Raspagliesi, Francesco Andreetta, Claudia Maldi, Elena Artioli, Grazia Mammoliti, Serafina Zanchi, Lucia Sikokis, Angelica Biglia, Nicoletta Parisi, Alessandro Mandato, Vincenzo Dario Carella, Claudia Cormio, Gennaro Marinaccio, Marco Puppo, Andrea Paolini, Biagio Borsotti, Lucia Scotto, Giulia Turinetto, Margherita Sangiolo, Dario Di Maio, Massimo Valabrega, Giorgio Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study |
title | Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study |
title_full | Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study |
title_fullStr | Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study |
title_full_unstemmed | Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study |
title_short | Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study |
title_sort | ki67 as a predictor of response to parp inhibitors in platinum sensitive brca wild type ovarian cancer: the mito 37 retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954459/ https://www.ncbi.nlm.nih.gov/pubmed/36831376 http://dx.doi.org/10.3390/cancers15041032 |
work_keys_str_mv | AT tuninettivalentina ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT ghisonieleonora ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT pignatasandro ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT picardoelisa ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT raspagliesifrancesco ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT andreettaclaudia ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT maldielena ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT artioligrazia ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT mammolitiserafina ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT zanchilucia ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT sikokisangelica ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT biglianicoletta ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT parisialessandro ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT mandatovincenzodario ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT carellaclaudia ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT cormiogennaro ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT marinacciomarco ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT puppoandrea ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT paolinibiagio ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT borsottilucia ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT scottogiulia ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT turinettomargherita ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT sangiolodario ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT dimaiomassimo ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy AT valabregagiorgio ki67asapredictorofresponsetoparpinhibitorsinplatinumsensitivebrcawildtypeovariancancerthemito37retrospectivestudy |